UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,405 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 10.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,479 shares of the biotechnology company’s stock after selling 3,405 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in AnaptysBio were worth $390,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ANAB. Fairmount Funds Management LLC bought a new position in shares of AnaptysBio in the fourth quarter worth about $24,050,000. Boxer Capital Management LLC bought a new position in shares of AnaptysBio in the fourth quarter worth about $17,212,000. Sanofi bought a new position in shares of AnaptysBio in the fourth quarter worth about $10,882,000. Soleus Capital Management L.P. bought a new position in shares of AnaptysBio in the fourth quarter worth about $5,481,000. Finally, Vanguard Group Inc. lifted its holdings in shares of AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock worth $24,411,000 after acquiring an additional 143,584 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ANAB shares. JPMorgan Chase & Co. upped their price objective on AnaptysBio from $36.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Wells Fargo & Company upped their price objective on AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Johnson Rice reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Wednesday, March 26th. HC Wainwright raised AnaptysBio from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $38.00 in a research note on Wednesday, June 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a research note on Thursday, May 29th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average price target of $42.38.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $23.60 on Thursday. The company has a market capitalization of $693.37 million, a PE ratio of -3.88 and a beta of -0.26. The company has a 50 day simple moving average of $20.38 and a two-hundred day simple moving average of $18.40. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Research analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its board has authorized a share repurchase plan on Monday, March 24th that permits the company to buyback $75.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.